LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF

• US 20140309236A1
• Filed: 10/09/2013
• Published: 10/16/2014
• Est. Priority Date: 09/25/2001
• Status: Active Grant

• Current Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Original Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Inventors: BANDO, Takuji, AOKI, Satoshi, KAWASAKI, Junichi, ISHIGAMI, Makoto, TANIGUCHI, Youichi, YABUUCHI, Tsuyoshi, FUJIMOTO, Kiyoshi, NISHIOKA, Yoshihiro, KOBAYASHI, Noriyuki, FUJIMURA, Tsutomu, TAKAHASHI, Masanori, ABE, Kaoru, NAKAGAWA, Tomonori, SHINHAMA, Koichi, UTSUMI, Naoto, TOMINAGA, Michiaki, OOI, Yoshihiro, YAMADA, Shohei, TOMIKAWA, Kenji
• Granted Patent: US 9,359,302 B2
• Time in Patent Office: Days
• US Class Current: 514/253.07
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: C07B 2200/13 Crystalline forms, e.g. polymorphs
• CPC Class Codes: C07D 215/22 attached in position 2 or 4
• CPC Class Codes: C07D 215/227 only one oxygen atom which is attached in position 2
• CPC Class Codes: Y10T 428/2982 Particulate matter [e.g., sphere, flake, etc.]

Abstract

The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.

Claims

1-48. -48. (canceled)

49. Anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

50. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less.

51. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

52. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

53. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less.

54. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

55. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

56. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

57. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

58. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

59. The anhydrous aripiprazole crystals according to claim 49, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

60. Anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

61. The anhydrous aripiprazole crystals according to claim 60, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less.

62. The anhydrous aripiprazole crystals according to claim 60, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

63. The anhydrous aripiprazole crystals according to claim 60, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

64. The anhydrous aripiprazole crystals according to claim 60, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less.

65. The anhydrous aripiprazole crystals according to claim 60, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

66. The anhydrous aripiprazole crystals according to claim 60, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

67. Anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thereogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

68. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less.

69. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

70. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

71. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less.

72. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

73. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

74. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

75. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

76. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

77. The anhydrous aripiprazole crystals according to claim 67, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

78. Anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

79. The anhydrous aripiprazole crystals according to claim 78, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less.

80. The anhydrous aripiprazole crystals according to claim 78, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

81. The anhydrous aripiprazole crystals according to claim 78, wherein the anhydrous aripiprazole crystals have a mean particle size of 50 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

82. The anhydrous aripiprazole crystals according to claim 78, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less.

83. The anhydrous aripiprazole crystals according to claim 78, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

84. The anhydrous aripiprazole crystals according to claim 78, wherein the anhydrous aripiprazole crystals have a mean particle size of 30 μ

m or less, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said anhydrous aripiprazole crystals in a 20 mL n-hexane solution of 0.5 g soy lecithin.

85. A process for preparing anhydrous aripiprazole crystals having low hygroscopicity, wherein said process comprises heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=12.6°

, 15.4°

, 17.3°

, 18.0°

, 18.6°

, 22.5°

, and 24.8°

using a Cu K_α

, x-ray;

an endothermic curve comprising a first endothermic peak at about 71°

C. and a second endothermic peak around 60°

to 120°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1477, 1378, 1187, 963, and 784 cm<sup>−

1</sup> on the IR (KBr) spectrum,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

86. The process according to claim 85, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

87. The process according to claim 85, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

88. The process according to claim 85, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

89. The process according to claim 85, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

97. The process according to any one of claims 85 to 96, wherein said process comprises heating the hydrous aripiprazole at 90-125°

C. for about 3-50 hours.

98. The process according to claim 97, wherein said process comprises heating the hydrous aripiprazole at 100°

C. for about 18 hours.

99. The process according to claim 97, wherein said process comprises heating the hydrous aripiprazole at 100°

C. for about 24 hours.

100. The process according to claim 97, wherein said process comprises heating the hydrous aripiprazole at 120°

C. for about 3 hours.

101. The process according to claim 97, wherein said process comprises heating the hydrous aripiprazole for about 18 hours at 100°

C. followed by additional heating for about 3 hours at 120°

C.

90. A process for preparing anhydrous aripiprazole crystals having low hygroscopicity, wherein said process comprises heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=12.6°

, 15.4°

, 17.3°

, 18.0°

, 18.6°

, 22.5°

, and 24.8°

using a Cu K_α

x-ray;

an endothermic curve comprising a first endothermic peak at about 71°

C. and a second endothermic peak around 60°

to 120°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1477, 1378, 1187, 963, and 784 cm<sup>−

1</sup> on the IR (KBr) spectrum,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

91. The process according to claim 90, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

92. The process according to claim 90, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

93. The process according to claim 90, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

94. The process according to claim 90, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

95. A process for preparing anhydrous aripiprazole crystals having low hygroscopicity, wherein said process comprises heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 3 using a Cu K_α

x-ray, and

an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5°

C./min) curve shown in FIG. 1,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole trysts have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

96. A process for preparing anhydrous aripiprazole crystals having low hygroscopicity, wherein said process comprises heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 3 using a Cu K_α

x-ray; and

an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5°

C./min) curve shown in FIG. 1,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

102. Anhydrous aripiprazole crystals having low hygroscopicity prepared by a process comprising heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=12.6°

, 15.4°

, 17.3°

, 18.0°

, 18.6°

, 22.5°

, and 24.8°

using a Cu K_α

x-ray;

an endothermic curve comprising a first endothermic peak at about 71°

C. and a second endothermic peak around 60°

to 120°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1477, 1378, 1187, 963, and 784 cm<sup>−

1</sup> on the IR (KBr) spectrum,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

103. The anhydrous aripiprazole crystals according to claim 102, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

104. The anhydrous aripiprazole crystals according to claim 102, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

105. The anhydrous aripiprazole crystals according to claim 102, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

106. The anhydrous aripiprazole crystals according to claim 102, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

114. The anhydrous aripiprazole crystals according to any one of claims 102 to 113, wherein said process comprises heating the hydrous aripiprazole at 90-125°

C. for about 3-50 hours.

115. The anhydrous aripiprazole crystals according to claim 114, wherein said process comprises heating the hydrous aripiprazole at 100°

C. for about 18 hours.

116. The anhydrous aripiprazole crystals according to claim 114, wherein said process comprises heating the hydrous aripiprazole at 100°

C. for about 24 hours.

117. The anhydrous aripiprazole crystals according to claim 114, wherein said process comprises heating the hydrous aripiprazole at 120°

C. for about 3 hours.

118. The anhydrous aripiprazole crystals according to claim 114, wherein said process comprises heating the hydrous aripiprazole for about 18 hours at 100°

C. followed by additional heating for about 3 hours at 120°

C.

107. Anhydrous aripiprazole crystals having low hygroscopicity prepared by a process comprising heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=12.6°

, 15.4°

, 17.3°

, 18.0°

, 18.6°

, 22.5°

, and 24.8°

using a Cu K_α

x-ray;

an endothermic curve comprising a first endothermic peak at about 71°

C. and a second endothermic peak around 60°

to 120°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1477, 1378, 1187, 963, and 784 cm<sup>−

1</sup> on the IR (KBr) spectrum,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

108. The anhydrous aripiprazole crystals according to claim 107, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

109. The anhydrous aripiprazole crystals according to claim 107, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

110. The anhydrous aripiprazole crystals according to claim 107, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

111. The anhydrous aripiprazole crystals according to claim 107, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

112. Anhydrous aripiprazole crystals having low hygroscopicity prepared by a process comprising heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 3 using a Cu K_α

x-ray; and

an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5°

C./min) curve shown in FIG. 1,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

113. Anhydrous aripiprazole crystals having low hygroscopicity prepared by a process comprising heating hydrous aripiprazole having one or more of the following properties:

a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 3 using a Cu K_α

x-ray; and

an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5°

C./min) curve shown in FIG. 1,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

119. A pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity and at least one pharmaceutically acceptable carrier, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

using a Cu K_α

, x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

120. The pharmaceutical composition according to claim 119, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

, x-ray.

121. The pharmaceutical composition according to claim 119, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

122. The pharmaceutical composition according to claim 119, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

123. The pharmaceutical composition according to claim 119, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

125. The pharmaceutical composition according to any one of claims 119 to 124, wherein said pharmaceutical composition comprises the anhydrous aripiprazole crystals in an amount effective to treat schizophrenia.

126. The pharmaceutical composition according to any one of claims 119 to 124, wherein said pharmaceutical composition is in the form of a solid oral tablet.

127. The pharmaceutical composition according to claim 126, wherein said solid oral tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

128. The pharmaceutical composition according to any one of claims 119 to 124, wherein said pharmaceutical composition is in the form of an oral flashmelt tablet.

129. The pharmaceutical composition according to claim 128, wherein said oral flashmelt tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

124. A pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity and at least one pharmaceutically acceptable carrier, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

130. A pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity and at least one pharmaceutically acceptable carrier, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

131. The pharmaceutical composition according to claim 130, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

132. The pharmaceutical composition according to claim 130, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

133. The pharmaceutical composition according to claim 130, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

134. The pharmaceutical composition according to claim 130, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

136. The pharmaceutical composition according to any one of claims 130 to 135, wherein said pharmaceutical composition comprises the anhydrous aripiprazole crystals in an amount effective to treat schizophrenia.

137. The pharmaceutical composition according to any one of claims 130 to 135, wherein said pharmaceutical composition is in the form of a solid oral tablet.

138. The pharmaceutical composition according to claim 137, wherein said solid oral tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

139. The pharmaceutical composition according to any one of claims 130 to 135, wherein said pharmaceutical composition is in the form of an oral flashmelt tablet.

140. The pharmaceutical composition according to claim 139, wherein said oral flashmelt tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

135. A pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity and at least one pharmaceutically acceptable carrier, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

141. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curie comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

142. The method according to claim 141, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

143. The method according to claim 141, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

144. The method according to claim 141, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

145. The method according to claim 141, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

146. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

147. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

148. The method according to claim 147, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0′

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

149. The method according to claim 147, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

150. The method according to claim 147, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

151. The method according to claim 147, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

152. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

153. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

154. The method according to claim 153, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

), and 22.1°

, using a Cu K_α

x-ray.

155. The method according to claim 153, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

156. The method according to claim 153, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

157. The method according to claim 153, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

158. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

159. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./rain); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

160. The method according to claim 159, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

161. The method according to claim 159, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IA (KBr) spectrum.

162. The method according to claim 159, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

163. The method according to claim 159, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

164. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

165. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

166. The method according to claim 165, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

167. The method according to claim 165, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

168. The method according to claim 165, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

169. The method according to claim 165, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

170. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

171. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

172. The method according to claim 171, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_y, x-ray.

173. The method according to claim 171, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

174. The method according to claim 171, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

175. The method according to claim 171, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

176. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

177. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

178. The method according to claim 177, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

179. The method according to claim 177, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

180. The method according to claim 177, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

181. The method according to claim 177, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

182. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

183. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

, x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

184. The method according to claim 183, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

185. The method according to claim 183, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

186. The method according to claim 183, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

187. The method according to claim 183, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

188. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

189. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

190. The method according to claim 189, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

191. The method according to claim 189, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

192. The method according to claim 189, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

193. The method according to claim 189, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

194. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

195. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

196. The method according to claim 195, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

197. The method according to claim 195, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

198. The method according to claim 195, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

199. The method according to claim 195, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

200. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

201. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

202. The method according to claim 201, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

203. The method according to claim 201, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

204. The method according to claim 201, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

205. The method according to claim 201, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

206. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

207. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=. 11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

208. The method according to claim 207, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

209. The method according to claim 207, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

210. The method according to claim 207, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

211. The method according to claim 207, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

212. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

213. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

214. The method according to claim 213, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

215. The method according to claim 213, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

216. The method according to claim 213, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

217. The method according to claim 213, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

218. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

219. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

220. The method according to claim 219, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

221. The method according to claim 219, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

222. The method according to claim 219, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

223. The method according to claim 219, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

224. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

225. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

226. The method according to claim 225, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

227. The method according to claim 225, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

228. The method according to claim 225, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

229. The method according to claim 225, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

230. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

231. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

232. The method according to claim 231, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

233. The method according to claim 231, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

234. The method according to claim 231, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

235. The method according to claim 231, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

236. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

237. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

238. The method according to claim 237, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

239. The method according to claim 237, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

240. The method according to claim 237, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

241. The method according to claim 237, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

242. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

243. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

244. The method according to claim 243, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

245. The method according to claim 243, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

246. The method according to claim 243, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

247. The method according to claim 243, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

248. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

249. A method for the treatment of autism which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

250. The method according to claim 249, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

251. The method according to claim 249, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

252. The method according to claim 249, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

253. The method according to claim 249, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

254. A method for the treatment of autism which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

255. A method for the treatment of autism which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./rain); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./rain).

256. The method according to claim 255, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

257. The method according to claim 255, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

258. The method according to claim 255, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

259. The method according to claim 255, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

260. A method for the treatment of autism which comprises administering to a patient in need thereof an effective amount of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

261. A method for the treatment of autism which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

262. The method according to claim 261, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

263. The method according to claim 261, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

264. The method according to claim 261, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

265. The method according to claim 261, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

266. A method for the treatment of autism which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

267. A method for the treatment of autism which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

, x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

268. The method according to claim 267, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

269. The method according to claim 267, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

270. The method according to claim 267, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

271. The method according to claim 267, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

272. A method for the treatment of autism which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of anhydrous aripiprazole crystals having low hygroscopicity per 1 kg of body weight, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

273. A method for the treatment of autism which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

274. The method according to claim 273, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

275. The method according to claim 273, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

276. The method according to claim 273, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

277. The method according to claim 273, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

278. A method for the treatment of autism which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

279. A method for the treatment of autism which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

280. The method according to claim 279, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

281. The method according to claim 279, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

282. The method according to claim 279, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

283. The method according to claim 279, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

284. A method for the treatment of autism which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of anhydrous aripiprazole crystals having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

285. A kit comprising:

a pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity in an amount effective to treat schizophrenia and at least one pharmaceutically acceptable carrier, and

instructions for using the pharmaceutical composition to treat schizophrenia,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray,

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

286. The kit according to claim 285, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray.

287. The kit according to claim 285, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

288. The kit according to claim 285, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

289. The kit according to claim 285, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

290. A kit comprising:

a pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity in an amount effective to treat schizophrenia and at least one pharmaceutically acceptable carrier, and

instructions for using the pharmaceutical composition to treat schizophrenia,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

291. A kit comprising:

a pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity in an amount effective to treat schizophrenia and at least one pharmaceutically acceptable carrier, and

instructions for using the pharmaceutical composition to treat schizophrenia,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have one or more of the following properties;

a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.03°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

, using a Cu K_α

x-ray;

an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm<sup>−

1</sup> on the IR (KBr) spectrum;

an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min); and

an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

292. The kit according to claim 291, wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum comprising characteristic peaks at 2θ

=11.0°

, 16.6°

, 19.3°

, 20.3°

, and 22.1°

using a Cu K_α

x-ray.

293. The kit according to claim 291, wherein the anhydrous aripiprazole crystals have an infrared absorption spectrum comprising infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm⁻

1 on the IR (KBr) spectrum.

294. The kit according to claim 291, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 141.5°

C. in a thermogravimetric or differential thermal analysis (heating rate 5°

C./min).

295. The kit according to claim 291, wherein the anhydrous aripiprazole crystals have an endothermic curve comprising an endothermic peak at about 140.7°

C. in a differential scanning calorimetry analysis (heating rate 5°

C./min).

296. A kit comprising:

a pharmaceutical composition comprising anhydrous aripiprazole crystals having low hygroscopicity in an amount effective to treat schizophrenia and at least one pharmaceutically acceptable carrier, and

instructions for using the pharmaceutical composition to treat schizophrenia,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the anhydrous aripiprazole crystals are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%,

wherein the anhydrous aripiprazole crystals have a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 5 using a Cu K_α

x-ray.

297. Anhydrous Aripiprazole Crystals B having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%, wherein the Anhydrous Aripiprazole Crystals B have a mean particle size of 50 μ

m or less.

298. The Anhydrous Aripiprazole Crystals B according to claim 297, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

299. The Anhydrous Aripiprazole Crystals B according to claim 297, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said Anhydrous Aripiprazole Crystals B in a 20 mL n-hexane solution of 0.5 g soy lecithin.

300. The Anhydrous Aripiprazole Crystals B according to claim 297, wherein the Anhdydrous Aripiprazole Crystals B have a mean particle size of 30 μ

m or less.

301. The Anhydrous Aripiprazole Crystals B according to claim 300, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

302. The Anhydrous Aripiprazole Crystals B according to claim 300, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said Anhydrous Aripiprazole Crystals B in a 20 mL n-hexane solution of 0.5 g soy lecithin.

303. Anhydrous Aripiprazole Crystals B having low hygroscopicity, wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%, wherein the Anhydrous Aripiprazole Crystals B have a mean particle size of 50 μ

m or less.

304. The Anhydrous Aripiprazole Crystals B according to claim 303, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

305. The Anhydrous Aripiprazole Crystals B according to claim 303, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said Anhydrous Aripiprazole Crystals B in a 20 mL n-hexane solution of 0.5 g soy lecithin.

306. The Anhydrous Aripiprazole Crystals B according to claim 303, wherein the Anhdydrous Aripiprazole Crystals B have a mean particle size of 30 μ

m or less.

307. The Anhydrous Aripiprazole Crystals B according to claim 306, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

308. The Anhydrous Aripiprazole Crystals B according to claim 306, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said Anhydrous Aripiprazole Crystals B in a 20 mL n-hexane solution of 0.5 g soy lecithin.

309. A process for preparing Anhydrous Aripiprazole Crystals B having low hygroscopicity, wherein said process comprises heating Hydrate A of aripiprazole,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

310. The process according to claim 309, wherein said process comprises heating Hydrate A of aripiprazole at 90-125°

C. for about 3-50 hours.

311. The process according to claim 309, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 18 hours.

312. The process according to claim 309, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 24 hours.

313. The process according to claim 309, wherein said process comprises heating Hydrate A of aripiprazole at 120°

C. for about 3 hours.

314. The process according to claim 309, wherein said process comprises heating Hydrate A of aripiprazole for about 18 hours at 100°

C. followed by additional heating for about 3 hours at 120°

C.

315. A process for preparing Anhydrous Aripiprazole Crystals B having low hygroscopicity, wherein said process comprises heating Hydrate A of aripiprazole,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

316. The process according to claim 315, wherein said process comprises heating Hydrate A of aripiprazole at 90-125°

C. for about 3-50 hours.

317. The process according to claim 315, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 18 hours.

318. The process according to claim 315, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 24 hours.

319. The process according to claim 315, wherein said process comprises heating Hydrate A of aripiprazole at 120°

C. for about 3 hours.

320. The process according to claim 315, wherein said process comprises heating Hydrate A of aripiprazole for about 18 hours at 100°

C. followed by additional heating for about 3 hours at 120°

C.

321. Anhydrous Aripiprazole Crystals B having low hygroscopicity prepared by a process comprising heating Hydrate A of aripiprazole,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

322. The Anhydrous Aripiprazole Crystals B according to claim 321, wherein said process comprises heating Hydrate A of aripiprazole at 90-125°

C. for about 3-50 hours.

323. The Anhydrous Aripiprazole Crystals B according to claim 321, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 18 hours.

324. The Anhydrous Aripiprazole Crystals B according to claim 321, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 24 hours.

325. The Anhydrous Aripiprazole Crystals B according to claim 321, wherein said process comprises heating Hydrate A of aripiprazole at 120°

C. for about 3 hours.

326. The Anhydrous Aripiprazole Crystals B according to claim 321, wherein said process comprises heating Hydrate A of aripiprazole for about 18 hours at 100°

C. followed by additional heating for about 3 hours at 120°

C.

327. Anhydrous Aripiprazole Crystals B having low hygroscopicity prepared by a process comprising heating Hydrate A of aripiprazole,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

328. The Anhydrous Aripiprazole Crystals B according to claim 327, wherein said process comprises heating Hydrate A of aripiprazole at 90-125°

C. for about 3-50 hours.

329. The Anhydrous Aripiprazole Crystals B according to claim 327, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 18 hours.

330. The Anhydrous Aripiprazole Crystals B according to claim 327, wherein said process comprises heating Hydrate A of aripiprazole at 100°

C. for about 24 hours.

331. The Anhydrous Aripiprazole Crystals B according to claim 327, wherein said process comprises heating Hydrate A of aripiprazole at 120°

C. for about 3 hours.

332. The Anhydrous Aripiprazole Crystals B according to claim 327, wherein said process comprises heating Hydrate A of aripiprazole for about 18 hours at 100°

C. followed by additional heating for about 3 hours at 120°

C.

333. A pharmaceutical composition comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity and at least one pharmaceutically acceptable carrier,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

334. The pharmaceutical composition according to claim 333, wherein said pharmaceutical composition comprises said Anhydrous Aripiprazole Crystals B in an amount effective to treat schizophrenia.

335. The pharmaceutical composition according to claim 333, wherein said pharmaceutical composition is in the form of a solid oral tablet.

336. The pharmaceutical composition according to claim 335, wherein said solid oral tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

337. The pharmaceutical composition according to claim 333, wherein said pharmaceutical composition is in the form of an oral flashmelt tablet.

338. The pharmaceutical composition according to claim 337, wherein said oral flashmelt tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

339. A pharmaceutical composition comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity and at least one pharmaceutically acceptable carrier,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

340. The pharmaceutical composition according to claim 339, wherein said pharmaceutical composition comprises said Anhydrous Aripiprazole Crystals B in an amount effective to treat schizophrenia.

341. The pharmaceutical composition according to claim 339, wherein said pharmaceutical composition is in the form of a solid oral tablet.

342. The pharmaceutical composition according to claim 341, wherein said solid oral tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

343. The pharmaceutical composition according to claim 339, wherein said pharmaceutical composition is in the form of an oral flashmelt tablet.

344. The pharmaceutical composition according to claim 343, wherein said oral flashmelt tablet has at least one dissolution rate selected from the group consisting of 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

345. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

346. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

347. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

348. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

349. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

350. A method for the treatment of schizophrenia which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

351. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

352. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

353. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

354. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

355. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

356. A method for the treatment of bipolar disorder which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

357. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

358. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

359. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

360. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

361. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

362. A method for the treatment of anxiety, depression, or mania which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

363. A method for the treatment of autism which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

364. A method for the treatment of autism which comprises administering to a patient in need thereof an effective amount of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

365. A method for the treatment of autism which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

366. A method for the treatment of autism which comprises administering to a patient in need thereof from about 0.1 milligrams to about 10 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity per 1 kg of body weight,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

367. A method for the treatment of autism which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

368. A method for the treatment of autism which comprises administering to a patient in need thereof a unit dose comprising from about 1 milligram to about 100 milligrams of Anhydrous Aripiprazole Crystals B having low hygroscopicity,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

369. A kit comprising:

a pharmaceutical composition comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity in an amount effective to treat schizophrenia and at least one pharmaceutically acceptable carrier, and

instructions for using the pharmaceutical composition to treat schizophrenia,

wherein said low hygroscopicity is defined as a moisture content of 0.40% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.

370. A kit comprising:

a pharmaceutical composition comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity in an amount effective to treat schizophrenia and at least one pharmaceutically acceptable carrier, and

instructions for using the pharmaceutical composition to treat schizophrenia,

wherein said low hygroscopicity is defined as a moisture content of 0.10% or less when the Anhydrous Aripiprazole Crystals B are placed for 24 hours in a dessicator maintained at a temperature of 60°

C. and a humidity level of 100%.